Clinical Trial Detail

NCT ID NCT02511106
Title AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

Age Groups: senior adult

No variant requirements are available.